Therefore, many AR PROTEC degraders like ARV-110 [58,59,60], ARD-61 [61], ARV-766 (phase I clinical trial, NCT05067140) [60], AR-LDD [60], ARCC-4 [62] are studied if depletion of AR can overcome the drug resistance of PCa. Here, AR is linked to posterior cortical atrophy.